Formulary Watch
Latest News
All News
Advertisement
In its latest round of cancer drug approvals, the FDA last week approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC).
FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic renal cell carcinoma.
FDA this week approved a new indication for BioThrax to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease.
In FDA’s latest approval of a new medication to treat multiple myeloma, the agency approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Most idiopathic pulmonary fibrosis patients have considerably impaired lung function and gastroesophageal reflux disease is the most common co-morbidity, according to initial results from the IPF-PRO Registry.
Manufactured by Adapt Pharma, Narcan is the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Up until now, naloxone has only been available in an injectable form.
FDA has approved cobimetinib (Cotellic, Genentech) to be used in combination with vemurafenib (Zelboraf) for the treatment of advanced melanoma.
The FDA accelerated approval for Darzalex injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or who are double-refractory to a PI and an immunomodulatory agent.
FDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.
Advertisement
FDA approved Yondelis (trabectedin), by Janssen Biotech for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.
FDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.
Sarilumab, an investigational, human antibody against the IL-6 receptor, is highly effective in the difficult-to-treat TNF-IR population in rheumatoid arthritis (RA), according to data presented during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California.
A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis negatively impacts patients.
The Food and Drug Administration last week approved Genvoya, marketed by Gilead Sciences, to treat HIV-1 infection.
FDA has approved talimogene laherparepvec (Imlygic, Amgen) for the treatment of unresectable melanoma lesions.
Deaths from drug overdoses are the leading cause of injury death in the United States, ahead of deaths linked to motor vehicles and firearms, according to the new 2015 National Drug Threat Assessment (NDTA), released by the Drug Enforcement Administration.
Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, will speak about the future of drug development in pulmonary fibrosis during the PFF Summit 2015: From Bench to Bedside conference, November 12-14 in Washington D.C.
After Valeant and Express Scripts cut ties with mail order specialty pharmacy Philidor Rx Services, the company said it would be closing.
Advancements in IV robotics are mitigating the risks of human error in the compounding process. The misconceptions of IV robotics are many, but there are also many real world examples of how hospitals and health systems are improving processes by implementing technology to support in-house sterile compounding.
FDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri Neohaler (glycopyrrolate) – which is one component of Utibron Neohaler -- for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
The FDA this week expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma - lowering the risk that melanoma will return following surgery.
A new online library or knowledge portal, the Type 2 Diabetes Genetics Beta, has been launched to provide open-access searching of genetic and clinical information on type 2 diabetes.
A pharmacist-led telemonitoring program reduced blood sugar levels in diabetics, according to a new study.
FDA has approved buprenorphine (Belbuca, Endo Pharmaceuticals) buccal film for use in patients with chronic pain.
FDA has approved idarucizumab (Praxbind, Boehringer Ingelheim) as the first reversal agent for Pradaxa.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
How PBMs are tackling behavioral health
2
Most commercial plans cover SC and IV oncology therapies at parity
3
The women’s health conversation still has a migraine-sized gap
4
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
5